ARVN
Arvinas, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.39
+0.86%Sep 1, 2026, 20:01 UTC
Arvinas, Inc. granted 45,696 restricted stock units to a newly hired employee on August 31, 2026, as an inducement award under Nasdaq Listing Rule 5635(c)(4).
Source:Aug 4, 2026, 14:06 UTC
Arvinas entered into an out-licensing agreement for VEPPANU with Rigel Pharmaceuticals in the first half of 2026.
Source:Aug 4, 2026, 13:51 UTC
Arvinas, Inc. reported Q2 2026 earnings of $2.58 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share, and compared to a loss of $0.84 per share in the same quarter last year.
Source:Aug 4, 2026, 11:00 UTC
Arvinas secured the first-ever regulatory approval of its PROTAC drug VEPPANU.
Jun 17, 2026, 00:00 UTC
Rigel Pharmaceuticals completed the acquisition of exclusive global rights to develop, manufacture and commercialize VEPPANU (vepdegestrant) from Arvinas entities and Pfizer.